Philips Sonicare Next-Generation DiamondClean 9900 Prestige is now available on Amazon; the brand’s most advanced, intelligent toothbrush that gives users real-time guidance alongside signature brushi

Philips (PHG) won a legal case against shareholders over its sleep-apnea device recall. The Dutch court rejected claims of misleading disclosures and slow action by management. Philips ADRs closed at $24.24, down 10.5% YTD. The recall cost Philips $2.96B in net losses over three years and a $1.1B settlement. The company returned to profitability in 2025 but earnings remain below pre-recall levels. The ruling does not address the US sales ban on Respironics devices, which remains a constraint.

A Dutch court dismissed shareholders' demands for an investigation into Philips' (AS:PHG) 2021 sleep apnea device recall, finding no grounds to question its policies or management practices. The ruling followed a review of internal documents, which showed the company's systems were based on international standards. Shareholders had alleged mismanagement and misinformation, but the court found no evidence of late disclosure of health risks.

FDA warned Philips (PHG) about a software malfunction in its Lumify Ultrasound System, linked to 4 deaths and 8 injuries. Philips advised stable connectivity and is developing a fix. PHG offers a 4.26% dividend yield, trades 6% below GF Value, and has a GF Score of 69. Institutional interest is cautiously positive.

The FDA issued an alert about Philips' Lumify ultrasound system due to a software issue causing scanning delays. Reports link the issue to deaths and injuries, according to the FDA. Philips is involved in addressing the problem.

Philips, GE HealthCare, and Siemens Healthineers face lawsuits from MR Access over alleged MRI patent infringements. The patents cover technology for improving MRI scan quality. MR Access, founded by MRI experts, seeks to license its patented technology.

Philips (NYSE:PHG, AEX: PHIA) launched the Lumea IPL 9900 Pro, an at-home hair removal device with audio guidance and motion tracking. The FDA-cleared device is priced at $699.95 and claims over 90% hair reduction after three treatments. Philips reported 2025 sales of EUR 18 billion.